The AML blasts were treated with low concentrations of the FLT3 inhibitor sunitinib, the PI3K inhibitor PF-04691502 and the GLI inhibitor GANT61 either alone or with the triple combination of agents. The gene discussed is GLI1; the disease is acute myeloid leukemia.